GleamWall
中文EN

ENTA ENANTA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1177648 · Fiscal year ends 09/30

Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.6%
TTM net income YoY16.7%
TTM EPS YoY38.8%
Revenue 3-yr CAGR-7.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-99.0%
Net margin-108.3%
FCF margin-67.9%
EBITDA margin-91.4%

Returns

ROE-94.2%
ROA-24.5%
ROIC (approx.)-106.7%
Asset turnover0.23x

Leverage & solvency

Liabilities / assets70.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage-4.43x

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q4*2026-09-302026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312024Q12024-12-31
Income statement
Revenue$12.87M$14.36M$17.16M$18.61M$15.12M$18.31M$14.93M$16.96M
R&D expense$26.12M$22.13M$19.44M$20.86M$23.81M$27.21M$28.07M$27.66M
SG&A expense$8.79M$9.47M$9.57M$9.01M$9.70M$10.00M$11.39M$12.85M
Operating income-$22.04M-$17.24M-$11.85M-$11.25M-$18.39M-$18.89M-$24.53M-$23.54M
Interest expense$3.54M$4.13M$3.32M$3.08M$2.39M$1.62M$1.71M$1.96M
Pretax income-$23.75M-$19.46M-$13.08M-$11.91M-$18.67M-$18.23M-$23.95M-$22.71M
Income tax-$27,000$36,000$7,000$24,000$32,000$29,000-$1.30M-$416,000
Net income-$23.72M-$19.50M-$13.09M-$11.94M-$18.70M-$18.25M-$22.64M-$22.29M
EBITDA-$20.88M-$16.05M-$10.64M-$10.02M-$17.10M-$17.68M-$23.32M-$22.65M
EPS (basic)—-0.67-0.45-0.42—-0.85-1.06-1.05
EPS (diluted)—-0.67-0.45-0.42—-0.85-1.06-1.05
Weighted avg. shares (diluted)—29.09M29.04M28.75M—21.38M21.36M21.24M
Balance sheet
Cash & equivalents$20.27M$33.42M$34.93M$37.44M$32.30M$44.81M$60.21M$84.35M
Short-term investments$174.24M$156.09M$128.85M$148.41M$156.57M$159.30M$133.16M$132.34M
Receivables$5.86M$6.53M$7.81M$8.49M$6.88M$8.33M$6.79M$7.72M
Current assets$205.99M$203.62M$178.41M$198.68M$204.34M$222.71M$242.86M$268.14M
PP&E, net$30.86M$31.94M$33.11M$34.31M$35.40M$36.62M$37.57M$37.37M
Total assets$275.58M$296.87M$314.70M$329.50M$280.73M$301.03M$322.99M$348.64M
Current liabilities$54.46M$54.17M$46.44M$44.73M$48.55M$44.55M$45.95M$49.05M
Total liabilities$195.38M$195.80M$198.12M$202.91M$216.01M$221.75M$229.46M$236.83M
Shareholders' equity$80.19M$101.07M$116.59M$126.59M$64.72M$79.28M$93.54M$111.82M
Shares outstanding29.14M29.12M29.06M29.02M21.39M21.38M21.38M21.33M
Cash flow statement
Operating cash flow-$13.73M-$9.97M-$7.16M-$11.70M-$6.49M$17.51M-$13.49M-$16.80M
Capital expenditure$41,000$7,000$15,000$143,000$1.46M$155,000$2.54M$8.74M
Free cash flow-$13.77M-$9.98M-$7.17M-$11.84M-$7.95M$17.35M-$16.03M-$25.55M
Investing cash flow$4.17M$14.01M$11.94M-$47.30M$2.30M-$26.48M-$4.37M$68.90M
Financing cash flow-$3.58M-$5.54M-$7.29M$64.14M-$8.32M-$6.42M-$6.89M-$4.99M
Depreciation & amortization$1.16M$1.19M$1.21M$1.23M$1.28M$1.21M$1.20M$889,000
Stock-based compensation$2.79M$3.68M$3.75M$3.81M$4.03M$4.18M$4.69M$5.67M

Free plan shows the latest 8 periods; Pro shows all 60 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.